Oruka Therapeutics (NASDAQ:ORKA) Given “Buy” Rating at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research report report published on Monday morning,Benzinga reports. They currently have a $151.00 price objective on the stock.

A number of other analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Guggenheim reissued a “buy” rating and issued a $200.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. Wall Street Zen downgraded Oruka Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, August 16th. Mizuho set a $120.00 price objective on Oruka Therapeutics in a report on Thursday, September 3rd. Finally, UBS Group lifted their target price on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, July 1st. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Stock Up 3.5%

Shares of Oruka Therapeutics stock opened at $74.48 on Monday. Oruka Therapeutics has a twelve month low of $25.11 and a twelve month high of $115.51. The firm’s 50-day moving average price is $91.84 and its 200 day moving average price is $80.45.

Oruka Therapeutics (NASDAQ:ORKA) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). As a group, analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, SVP Arjun Agarwal sold 9,999 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $80.60, for a total value of $805,919.40. Following the transaction, the senior vice president directly owned 14,219 shares of the company’s stock, valued at $1,146,051.40. This trade represents a 41.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $74.81, for a total transaction of $523,670.00. Following the completion of the transaction, the insider directly owned 31,771 shares in the company, valued at $2,376,788.51. This trade represents a 18.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 154,950 shares of company stock worth $14,102,680. Insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ORKA. BlackRock Inc. purchased a new position in Oruka Therapeutics during the second quarter worth about $474,916,000. Jupiter Topco LLC purchased a new stake in shares of Oruka Therapeutics in the 2nd quarter valued at approximately $130,968,000. Remedium Capital Partners LLC grew its stake in shares of Oruka Therapeutics by 0.9% in the 1st quarter. Remedium Capital Partners LLC now owns 1,565,661 shares of the company’s stock valued at $76,796,000 after buying an additional 13,247 shares during the period. Avidity Partners Management LP grew its stake in shares of Oruka Therapeutics by 15.1% in the 1st quarter. Avidity Partners Management LP now owns 760,424 shares of the company’s stock valued at $37,299,000 after buying an additional 100,000 shares during the period. Finally, Bank of America Corp DE acquired a new stake in shares of Oruka Therapeutics during the 2nd quarter worth approximately $33,578,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.